Neurocrine Biosciences Inc (NBIX): Cost of Revenue
$52.10M
Year ended 2025-12-31
+31.0%
3-year compound annual growth
+38.8%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.10M | +53.2% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $34.00M | -14.4% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $39.70M | +71.1% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $23.20M | +62.2% | 2025-02-10, From 2022-01-01 |
| 2021-12-31 | $14.30M | +41.6% | 2024-02-09, From 2021-01-01 |
| 2020-12-31 | $10.10M | n/a | 2023-02-09, From 2020-01-01 |
| No annual figure between 2018-12-31 and 2020-12-31. | |||
| 2018-12-31 | $4.89M | +289.9% | 2019-02-08, From 2018-01-01 |
| 2017-12-31 | $1.25M | n/a | 2019-02-08, From 2017-01-01 |
| 2016-12-31 | $0 | n/a | 2019-02-08, From 2016-01-01 |
| 2015-12-31 | $0 | n/a | 2018-02-13, From 2015-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $52.10M | +53.2% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $83.70M | +9.8% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $790.50M | -21.8% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $868.00M | -40.7% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $228.77M | +43.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $415.97M | -3.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $73.04M | -64.0% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $19.07M | +55.5% |
| Biogen Inc. (BIIB) | 2025-12-31 | $2.40B | +4.1% |
Compare NBIX, EXEL, QGEN, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗